Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Financial press releases

05 July 2016

GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris

08 June 2016

GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

24 May 2016

GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext’s regulated market in Paris

29 February 2016

GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy

10 September 2015

GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010

23 July 2015

GenSight Biologics Closes $36 Million Series B Preferred Stock Financing

06 July 2015

GenSight Biologics Appoints Thomas Gidoin as Chief Financial Officer & Michael Wyzga to Board of Directors

06 January 2015

Sight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total € 18.5 million funding for SIGHT AGAIN as part of the Investment for the Future

06 May 2014

GenSight Biologics appoints Jean-Philippe Combal as Chief Operating Officer

08 April 2013

GenSight Biologics announced today the closing of a €32 million Series A financing for Ophthalmic Gene Therapy.

  • View previous 9 articles
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page